{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-035535","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.305597+00:00","generated_at":"2026-05-23T06:04:58.315171+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"CERo files Series D Preferred Stock designation; regains Nasdaq bid price compliance","bullets":["Filed Certificate of Designations for Series D convertible preferred stock effective April 22, 2025, part of previously reported securities purchase agreement.","April 24 closing price was $1.11, ending 26 consecutive trading days below $1.00.","No longer imminent risk of failing Nasdaq's minimum bid price requirement, though future risk remains.","Corporate presentation dated April 2025 furnished; exhibit contains no new specific operational or financial data."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-035535","json":"https://secwatch.observer/filing/0001213900-25-035535.json","markdown":"https://secwatch.observer/filing/0001213900-25-035535.md","text":"https://secwatch.observer/filing/0001213900-25-035535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/0001213900-25-035535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/ea0239321-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T06:04:58.315171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4eb1f82da50ad2ad8f09434676e287514a6abae6","claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations for Series D convertible preferred stock (effective 2025-04-22).","evidence_excerpt":"On April 22, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/0001213900-25-035535-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-04-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}